Skip to main content

Table 1 Baseline characteristics of all patients treated or not treated with anticoagulants

From: Benefit profile of anticoagulant therapy in sepsis: a nationwide multicentre registry in Japan

 

Overall (n = 2663)

Anticoagulant group (n = 1247)

Control group (n = 1416)

P value

Patient characteristics

 Age in years

73 (63–81)

72 (62–80)

73 (63–81)

0.034

 Male sex

1576 (59 %)

716 (57 %)

860 (61 %)

0.089

Illness severity

 SIRS score

3 (2–4)

3 (2–4)

3 (2–4)

0.508

 SOFA score

9 (6–12)

10 (8–13)

8 (5–11)

<0.001

 APACHE II score

22 (16–28)

23 (18–29)

21 (16–27)

<0.001

 ISTH DIC score

3 (1–4)

4 (2–5)

2 (1–4)

<0.001

 JAAM DIC score

4 (2–6)

5 (3–6)

3 (2–5)

<0.001

Source of ICU admission

   

<0.001

 Emergency department

1256 (47 %)

527 (42 %)

729 (52 %)

-

 Ward

711 (27 %)

366 (29 %)

345 (24 %)

-

 Other hospital

696 (26 %)

354 (28 %)

342 (24 %)

-

Pre-existing condition

 Liver insufficiency

19 (1 %)

12 (1 %)

7 (1 %)

0.171

 Chronic heart failure

143 (5 %)

76 (6 %)

67 (5 %)

0.122

 Chronic respiratory disorder

102 (4 %)

42 (3 %)

60 (4 %)

0.266

 Chronic haemodialysis

209 (8 %)

84 (7 %)

125 (9 %)

0.051

 Immunocompromised

280 (11 %)

130 (10 %)

150 (11 %)

0.899

New organ dysfunction (SOFA sub-scores ≥2)

 Respiratory

1792 (88 %)

851 (68 %)

941 (67 %)

0.341

 Cardiovascular

1761 (66 %)

934 (75 %)

827 (58 %)

<0.001

 Renal

1279 (48 %)

707 (57 %)

572 (40 %)

<0.001

 Hepatic

441 (17 %)

253 (20 %)

188 (13 %)

<0.001

 Coagulation

957 (36 %)

591 (47 %)

366 (26 %)

<0.001

Primary source of infection

   

<0.001

 Abdomen

881 (33 %)

460 (37 %)

421 (30 %)

-

 Lung

677 (25 %)

269 (22 %)

408 (29 %)

-

 Urinary tract

456 (17 %)

221 (18 %)

235 (17 %)

-

 Bone/soft tissue

309 (12 %)

146 (12 %)

163 (12 %)

-

 Central nervous system

57 (2 %)

30 (2 %)

27 (2 %)

-

 Other/unknown

283 (11 %)

121 (10 %)

162 (11 %)

-

Other therapeutic interventions

 Immunoglobulin

800 (30 %)

590 (47 %)

210 (15 %)

<0.001

 Low-dose steroid

624 (23 %)

401 (32 %)

223 (16 %)

<0.001

 Renal replacement therapy

830 (31 %)

566 (45 %)

264 (19 %)

<0.001

 PMX-DHP

574 (22 %)

410 (33 %)

164 (12 %)

<0.001

 Surgical intervention

1153 (43 %)

617 (50 %)

536 (38 %)

<0.001

  1. Data are expressed as group medians (interquartile range) or proportion (%). SIRS Systemic Inflammatory Response Syndrome, SOFA Sequential Organ Failure Assessment, APACHE Acute Physiology and Chronic Health Evaluation, ISTH International Society on Thrombosis and Haemostasis, DIC disseminated intravascular coagulation, JAAM Japanese Association for Acute Medicine, ICU intensive care unit, PMX-DHP polymyxin B direct haemoperfusion